Cargando…

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures

OBJECTIVE: Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Altalib, Hamada, Grinnell, Todd, Cantu, David, Ikedo, Fábio, Vieira, Mariana, Zhang, Yi, Blum, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712463/
https://www.ncbi.nlm.nih.gov/pubmed/35908275
http://dx.doi.org/10.1002/epi4.12635
_version_ 1784841793738637312
author Altalib, Hamada
Grinnell, Todd
Cantu, David
Ikedo, Fábio
Vieira, Mariana
Zhang, Yi
Blum, David
author_facet Altalib, Hamada
Grinnell, Todd
Cantu, David
Ikedo, Fábio
Vieira, Mariana
Zhang, Yi
Blum, David
author_sort Altalib, Hamada
collection PubMed
description OBJECTIVE: Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults with focal seizures. METHODS: This post‐hoc analysis evaluated data pooled from three Phase III, randomized, double‐blind, placebo‐controlled trials (BIA‐2093‐301, ‐302, ‐304). After an 8‐week baseline period, patients were randomized equally to receive placebo, ESL 400 mg (not reported here), 800 mg, or 1200 mg QD (up to 2‐week titration; 12‐week maintenance; optional open‐label extension [OLE]). Incidences of psychiatric TEAEs were evaluated according to three separate criteria: medical history of psychiatric disorders (yes/no); baseline use of psychotropic drugs (yes/no); Montgomery–Åsberg Depression Rating Scale (MADRS) score at baseline (0–6: normal; 7–19: mild depression; 20–34: moderate depression). RESULTS: The analysis populations comprised 1251 patients for the controlled study period and 1137 patients for the 1‐year OLE. Psychiatric TEAE incidence was similar between patients taking ESL and placebo in the controlled and OLE study periods and was not related to ESL dose. Psychiatric TEAEs generally occurred more frequently in patients with a medical history of psychiatric disorders, using psychotropic drugs, or with depressive symptoms than in those without a history, not using psychotropic drugs, or with no depressive symptoms. Depression and anxiety were the most frequently reported psychiatric TEAEs. SIGNIFICANCE: Overall, in clinical trials of ESL in adults with focal seizures, incidences of psychiatric events were not statistically different between patients taking ESL and placebo, were not related to ESL dose, and generally occurred more frequently in patients with baseline psychiatric symptoms or a history of psychiatric disorders. Long‐term exposure to ESL was not associated with a marked increase in the incidence of psychiatric TEAEs.
format Online
Article
Text
id pubmed-9712463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97124632022-12-02 Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures Altalib, Hamada Grinnell, Todd Cantu, David Ikedo, Fábio Vieira, Mariana Zhang, Yi Blum, David Epilepsia Open Original Articles OBJECTIVE: Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults with focal seizures. METHODS: This post‐hoc analysis evaluated data pooled from three Phase III, randomized, double‐blind, placebo‐controlled trials (BIA‐2093‐301, ‐302, ‐304). After an 8‐week baseline period, patients were randomized equally to receive placebo, ESL 400 mg (not reported here), 800 mg, or 1200 mg QD (up to 2‐week titration; 12‐week maintenance; optional open‐label extension [OLE]). Incidences of psychiatric TEAEs were evaluated according to three separate criteria: medical history of psychiatric disorders (yes/no); baseline use of psychotropic drugs (yes/no); Montgomery–Åsberg Depression Rating Scale (MADRS) score at baseline (0–6: normal; 7–19: mild depression; 20–34: moderate depression). RESULTS: The analysis populations comprised 1251 patients for the controlled study period and 1137 patients for the 1‐year OLE. Psychiatric TEAE incidence was similar between patients taking ESL and placebo in the controlled and OLE study periods and was not related to ESL dose. Psychiatric TEAEs generally occurred more frequently in patients with a medical history of psychiatric disorders, using psychotropic drugs, or with depressive symptoms than in those without a history, not using psychotropic drugs, or with no depressive symptoms. Depression and anxiety were the most frequently reported psychiatric TEAEs. SIGNIFICANCE: Overall, in clinical trials of ESL in adults with focal seizures, incidences of psychiatric events were not statistically different between patients taking ESL and placebo, were not related to ESL dose, and generally occurred more frequently in patients with baseline psychiatric symptoms or a history of psychiatric disorders. Long‐term exposure to ESL was not associated with a marked increase in the incidence of psychiatric TEAEs. John Wiley and Sons Inc. 2022-08-30 /pmc/articles/PMC9712463/ /pubmed/35908275 http://dx.doi.org/10.1002/epi4.12635 Text en © 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Altalib, Hamada
Grinnell, Todd
Cantu, David
Ikedo, Fábio
Vieira, Mariana
Zhang, Yi
Blum, David
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title_full Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title_fullStr Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title_full_unstemmed Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title_short Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
title_sort psychiatric adverse events in three phase iii trials of eslicarbazepine acetate for focal seizures
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712463/
https://www.ncbi.nlm.nih.gov/pubmed/35908275
http://dx.doi.org/10.1002/epi4.12635
work_keys_str_mv AT altalibhamada psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT grinnelltodd psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT cantudavid psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT ikedofabio psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT vieiramariana psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT zhangyi psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures
AT blumdavid psychiatricadverseeventsinthreephaseiiitrialsofeslicarbazepineacetateforfocalseizures